ProMIS Neurosciences initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of ProMIS Neurosciences (PMN) with a Buy rating and $4 price target ProMIS is an emerging biotechnology company focused on developing novel therapeutic and vaccine-based approaches to address serious unmet medical needs in neurology, the analyst tells investors in a research note.